This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
J&J's Coronavirus Vaccine Studies Paused Post Adverse Event
by Zacks Equity Research
J&J's (JNJ) large phase III ENSEMBLE study on its coronavirus vaccine candidate, JNJ-78436735, is expected to enroll 60,000 adult participants and compares a single dose of the vaccine to placebo.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $36.82, marking a +0.08% move from the previous day.
Pfizer's (PFE) Ibrance Fails in Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) Ibrance is marketed for the treatment of HR+, HER2- advanced or metastatic breast cancer but not for any early breast cancer indication.
Pharma Stock Roundup: LLY, AZN, PFE, GSK Progress on Coronavirus Programs
by Kinjel Shah
Lilly (LLY), Pfizer (PFE) and AstraZeneca (AZN) provide updates on their coronavirus vaccine/treatment programs.
Here's Why Small-Cap ETFs Are Hitting New Highs
by Sweta Killa
Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.
Pfizer, BioNTech Begin EU Rolling Filing of Coronavirus Vaccine
by Zacks Equity Research
Pfizer (PFE) and partner BioNTech start rolling review of their coronavirus vaccine candidate, BNT162b2, in Europe.
SpringWorks Inks Deal With Pfizer for Nirogacestat Combo
by Zacks Equity Research
SpringWorks (SWTX) inks a collaboration deal with Pfizer to evaluate nirogacestat along with the latter's BCMA-targeted therapy PF-06863135 for treating relapsed/refractory multiple myeloma. Stock up.
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.75, moving +1.02% from the previous trading session.
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MRNA, AZN, PFE and BNTX
AstraZeneca Resumes Japan Study on Coronavirus Vaccine Candidate
by Zacks Equity Research
AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in Japan resume. The U.S. study remains on hold.
Moderna Coronavirus Vaccine May Not Be Ready Before US Elections
by Zacks Equity Research
Moderna (MRNA) does not expect to apply for an emergency use authorization for its mRNA-based coronavirus before the U.S. presidential election scheduled on Nov 3.
Pharma Stock Roundup: FDA Approves New Uses of PFE, JNJ & GSK's Drugs
by Kinjel Shah
New indications of Glaxo's (GSK) Nucala J&J's (JNJ) Simponi Aria and Pfizer's (PFE) Xeljanz get FDA's nod.
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
by Zacks Equity Research
The Zacks Industry Rank Highlights: Gilead, Pfizer, Moderna, Johnson & Johnson and AstraZeneca
Zacks Market Edge Highlights: Chevron, Exxon Mobil, BP, Pfizer and Bank of America
by Zacks Equity Research
Zacks Market Edge Highlights: Chevron, Exxon Mobil, BP, Pfizer and Bank of America
Should you Buy Big Dividend Paying Stocks?
by Tracey Ryniec
ExxonMobil has a dividend yielding almost 10%. Is it risky to buy the big dividend payers or is it a golden opportunity?
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
5 Vaccine Stocks to Buy Now
by John Blank
The COVID-19 sponsor companies are either in the Zacks Large Cap Pharma industry, or in Zacks Biomedical and Genetics industry.
Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH
by Zacks Equity Research
Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.
AbbVie Elezanumab Gets FDA's Fast Track and Orphan Drug Tags
by Zacks Equity Research
AbbVie's (ABBV) elezanumab is presently being evaluated in a phase II study for spinal cord injury.
Pfizer's (PFE) Xeljanz Gets FDA Approval for 4th Indication
by Zacks Equity Research
Pfizer's (PFE) Xeljanz gets approval for children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).
Pfizer (PFE) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $36.39, moving +0.94% from the previous trading session.
The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK
Novavax Begins Phase III Study on Coronavirus Vaccine in the UK
by Zacks Equity Research
Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.
Pfizer Seeks Xalkori's Label Expansion, Gets Priority Review
by Zacks Equity Research
Pfizer's (PFE) sNDA seeking label expansion of lung cancer drug, Xalkori, for a hematologic indication gets priority review from the FDA.
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates
by Kinjel Shah
J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.